DiaMedica Therapeutics (DMAC) Competitors $5.05 +0.17 (+3.48%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$5.29 +0.24 (+4.75%) As of 07/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, and UPBShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors Maravai LifeSciences Iovance Biotherapeutics Urogen Pharma Tilray Brands Tango Therapeutics Stoke Therapeutics Prime Medicine Dianthus Therapeutics Phathom Pharmaceuticals Upstream Bio Maravai LifeSciences (NASDAQ:MRVI) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership. Does the media prefer MRVI or DMAC? In the previous week, DiaMedica Therapeutics had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for DiaMedica Therapeutics and 6 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.90 beat DiaMedica Therapeutics' score of 0.67 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MRVI or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-67.14% -12.91% -6.87% DiaMedica Therapeutics N/A -61.35%-55.53% Which has higher valuation and earnings, MRVI or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$241.86M2.83-$144.85M-$1.14-2.36DiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-7.89 Do analysts recommend MRVI or DMAC? Maravai LifeSciences presently has a consensus price target of $6.64, suggesting a potential upside of 146.80%. DiaMedica Therapeutics has a consensus price target of $10.75, suggesting a potential upside of 112.87%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of MRVI or DMAC? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, MRVI or DMAC? Maravai LifeSciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. SummaryMaravai LifeSciences and DiaMedica Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$209.27M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-7.8921.1828.1020.05Price / SalesN/A286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book5.328.378.665.87Net Income-$24.44M-$55.19M$3.25B$258.55M7 Day Performance20.81%5.88%4.22%3.73%1 Month Performance32.55%17.33%10.51%11.75%1 Year Performance38.74%4.42%34.40%18.03% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.4964 of 5 stars$5.05+3.5%$10.75+112.9%+36.9%$209.27MN/A-7.8920News CoverageInsider TradeMRVIMaravai LifeSciences3.6215 of 5 stars$2.67-2.2%$6.64+148.6%-68.4%$679.94M$259.18M-2.34610Options VolumeIOVAIovance Biotherapeutics4.6281 of 5 stars$2.01+7.5%$12.22+508.1%-66.8%$671.20M$164.07M-1.62500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeURGNUrogen Pharma4.5114 of 5 stars$14.49+1.8%$32.86+126.8%+15.8%$668.13M$90.40M-4.56200TLRYTilray Brands1.8077 of 5 stars$0.66+13.1%$1.92+191.8%-61.3%$661.07M$788.94M-0.632,650Upcoming EarningsOptions VolumeTNGXTango Therapeutics1.6657 of 5 stars$6.09+2.7%$12.20+100.3%-30.8%$660.12M$40.99M-4.9990Positive NewsSTOKStoke Therapeutics4.2583 of 5 stars$12.06+1.7%$24.75+105.2%-10.0%$658.48M$36.56M15.27100PRMEPrime Medicine3.8602 of 5 stars$4.80+10.3%$10.08+110.1%-25.5%$645.57M$3.85M-2.34234Gap DownHigh Trading VolumeDNTHDianthus Therapeutics1.3354 of 5 stars$20.03-0.1%$53.00+164.6%-23.5%$644.17M$6.24M-6.9580Positive NewsPHATPhathom Pharmaceuticals4.3202 of 5 stars$9.06-1.3%$17.50+93.2%-14.6%$632.48M$55.25M-1.73110Positive NewsUPBUpstream Bio1.9063 of 5 stars$11.73+2.2%$56.50+381.7%N/A$631.00M$2.30M0.0038News Coverage Related Companies and Tools Related Companies Maravai LifeSciences Alternatives Iovance Biotherapeutics Alternatives Urogen Pharma Alternatives Tilray Brands Alternatives Tango Therapeutics Alternatives Stoke Therapeutics Alternatives Prime Medicine Alternatives Dianthus Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Upstream Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
